Cytokinetics(US:CYTK) Globenewswire·2025-10-13 23:47Core Points - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock from December 27, 2023, to May 6, 2025, about the lead plaintiff deadline on November 17, 2025 [1] - Investors who purchased Cytokinetics stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed against Cytokinetics due to alleged false and misleading statements regarding the New Drug Application for aficamten [5] Company Information - The lawsuit claims that Cytokinetics misrepresented the timeline for the FDA approval of aficamten, stating that approval was expected in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [5] - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4] Legal Process - To join the class action, investors can visit the provided link or contact Rosen Law Firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]